Jiangsu Kanion Pharmaceutical Co.Ltd(600557) independent director
On matters related to the 14th meeting of the 7th board of directors
Prior approval opinion
As an independent director of Jiangsu Kanion Pharmaceutical Co.Ltd(600557) (hereinafter referred to as “the company”), in accordance with the relevant provisions of the company law, the securities law, the rules for independent directors of listed companies, the articles of association and other laws, regulations and normative documents, we have reviewed the relevant materials in advance, and hereby express the following opinions:
1. Prior approval opinions on re employment of Lixin Certified Public Accountants (special general partnership) as the auditor of the company’s 2022 financial report
The prior approval opinions of independent directors are as follows: after careful and comprehensive review of the basic materials of Lixin Certified Public Accountants (special general partnership), we believe that Lixin Certified Public Accountants (special general partnership) has securities and futures business licenses; Have the professional competence and independence to provide audit services for listed companies, and be able to audit the company’s financial reports objectively and independently; We unanimously agree to renew the appointment of Lixin Certified Public Accountants (special general partnership) as the auditor of the company’s 2022 financial report, and agree to submit the proposal to the 14th meeting of the seventh board of directors for deliberation.
2. Prior approval opinions on re employment of Lixin Certified Public Accountants (special general partnership) as the company’s internal control audit institution in 2022
The prior approval opinions of independent directors are as follows: after careful and comprehensive review of the basic materials of Lixin Certified Public Accountants (special general partnership), we believe that Lixin Certified Public Accountants (special general partnership) has the professional competence and independence to provide audit services for listed companies, and can be objective Independently audit the internal control of the company; We agreed to renew the appointment of Lixin Certified Public Accountants (special general partnership) as the company’s internal control audit institution in 2022, and agreed to submit the proposal to the 14th meeting of the seventh board of directors for deliberation.
3. Prior approval opinions on daily connected transactions in 2022
Independent directors have expressed their prior approval opinions on this: 1. The above proposal belongs to related party transactions, and the company shall perform the approval procedures and information disclosure obligations of the board of directors and the general meeting of shareholders in accordance with relevant regulations. 2. We have communicated with relevant personnel of the company on the above proposal, consulted relevant materials and had a more detailed understanding of the above proposal. 3. The above transactions have followed the principles of fairness, impartiality and fairness, have not harmed the interests of the company and minority shareholders, and comply with the relevant provisions of China Securities Regulatory Commission and Shanghai Stock Exchange. We agree to submit the above proposal to the 14th meeting of the seventh board of directors of the company for deliberation.
Independent directors: Chen Kaixian, Dong Qiang, Xu Min March 2, 2022
